Shattuck Labs (STTK) News Today → This Could be Your “Big Money” AI Moment (From InvestorPlace) (Ad) Free STTK Stock Alerts $7.45 -0.46 (-5.82%) (As of 05:19 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 4:40 AM | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Earns Buy Rating from HC WainwrightMay 16, 2024 | morningstar.comShattuck Labs Inc Ordinary SharesMay 16, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Shattuck Labs (NASDAQ:STTK)May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Shattuck Labs Amid Promising Clinical Updates and Market PotentialMay 15, 2024 | marketbeat.comShattuck Labs (NASDAQ:STTK) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $28.00 target price on shares of Shattuck Labs in a research note on Wednesday.May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: Shattuck Labs’ Promising Clinical Developments in HR-MDS and AML TreatmentMay 14, 2024 | globenewswire.comShattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 CongressMay 14, 2024 | marketbeat.comShattuck Labs (NASDAQ:STTK) Sees Unusually-High Trading VolumeShattuck Labs (NASDAQ:STTK) Sees Large Volume IncreaseMay 14, 2024 | marketbeat.comShattuck Labs (NASDAQ:STTK) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $12.00 price target on shares of Shattuck Labs in a report on Tuesday.May 9, 2024 | investing.comShattuck Labs Inc (STTK)May 4, 2024 | finance.yahoo.comShattuck Labs Inc (STTK) Reports First Quarter 2024 Financial ResultsMay 4, 2024 | finance.yahoo.comShattuck Labs First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | marketbeat.comShattuck Labs (NASDAQ:STTK) Posts Earnings Results, Beats Estimates By $0.08 EPSShattuck Labs (NASDAQ:STTK - Get Free Report) released its earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.08. Shattuck Labs had a negative net margin of 5,268.44% and a negative return on equity of 63.08%. The business had revenue of $1.15 million during the quarter, compared to analysts' expectations of $0.30 million. Shattuck Labs's quarterly revenue was up 2200.0% compared to the same quarter last year.May 3, 2024 | marketbeat.comShattuck Labs (NASDAQ:STTK) Given Buy Rating at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $12.00 price objective on shares of Shattuck Labs in a report on Friday.May 2, 2024 | investorplace.comSTTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | markets.businessinsider.comShattuck Labs: Buy Rating Affirmed on Strong Q1 Financials and Promising Clinical MilestonesMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Shattuck Labs Ahead of Key Clinical Trial Updates on SL-172154May 2, 2024 | marketbeat.comShattuck Labs (NASDAQ:STTK) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $28.00 price target on shares of Shattuck Labs in a research note on Thursday.May 2, 2024 | globenewswire.comShattuck Labs Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 29, 2024 | marketbeat.comShattuck Labs (NASDAQ:STTK) Reaches New 12-Month High at $11.19Shattuck Labs (NASDAQ:STTK) Sets New 1-Year High at $11.19April 20, 2024 | ca.finance.yahoo.comSTTK May 2024 7.500 callApril 18, 2024 | finance.yahoo.comOwning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),April 9, 2024 | globenewswire.comShattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024April 9, 2024 | markets.businessinsider.comStrong Buy Rating for Shattuck Labs on Innovative Immunotherapy Pipeline and LeadershipApril 1, 2024 | globenewswire.comShattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare ConferenceMarch 16, 2024 | finance.yahoo.comSTTK Apr 2024 17.500 callMarch 16, 2024 | finance.yahoo.comSTTK Apr 2024 7.500 putMarch 11, 2024 | insidertrades.comInsider Selling: Shattuck Labs, Inc. (NASDAQ:STTK) Insider Sells 16,004 Shares of StockMarch 6, 2024 | finance.yahoo.comShattuck Labs Full Year 2023 Earnings: Beats ExpectationsMarch 6, 2024 | marketbeat.comShattuck Labs (NASDAQ:STTK) Sets New 52-Week High at $11.11Shattuck Labs (NASDAQ:STTK) Hits New 52-Week High at $11.11March 4, 2024 | globenewswire.comShattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D.March 2, 2024 | markets.businessinsider.comBuy Rating Justified: Shattuck Labs’ Breakthrough in Cancer Immunotherapy and Strong FinancialsMarch 1, 2024 | marketbeat.comShattuck Labs, Inc. (NASDAQ:STTK) Sees Significant Increase in Short InterestShattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) saw a significant growth in short interest in February. As of February 15th, there was short interest totalling 1,230,000 shares, a growth of 64.2% from the January 31st total of 749,300 shares. Based on an average daily volume of 1,670,000 shares, the short-interest ratio is presently 0.7 days.March 1, 2024 | marketbeat.comShattuck Labs' (STTK) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $12.00 price target on shares of Shattuck Labs in a research report on Friday.March 1, 2024 | markets.businessinsider.comShattuck Labs (STTK) Receives a Buy from TD CowenFebruary 29, 2024 | globenewswire.comShattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business HighlightsFebruary 26, 2024 | globenewswire.comShattuck Labs Announces Participation in Upcoming March ConferencesFebruary 23, 2024 | finance.yahoo.comSTTK Mar 2024 17.500 callFebruary 22, 2024 | marketbeat.comShattuck Labs (STTK) Set to Announce Quarterly Earnings on FridayShattuck Labs (NASDAQ:STTK) will be releasing earnings on Friday, February 23, Yahoo Finance reports.February 21, 2024 | benzinga.comShattuck Labs Stock (NASDAQ:STTK) Dividends: History, Yield and DatesFebruary 17, 2024 | finance.yahoo.comSTTK Mar 2024 5.000 putFebruary 17, 2024 | finance.yahoo.comSTTK Mar 2024 10.000 callFebruary 17, 2024 | finance.yahoo.comSTTK Mar 2024 10.000 putFebruary 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: Shattuck Labs’ Promising Partnerships and Clinical AdvancementsFebruary 14, 2024 | prnewswire.comOno Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion ProteinsFebruary 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Shattuck Labs (STTK)February 13, 2024 | finance.yahoo.comShattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory DiseasesFebruary 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Molina Healthcare (MOH)January 26, 2024 | marketbeat.comShattuck Labs, Inc. (NASDAQ:STTK) Sees Large Decrease in Short InterestShattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 999,300 shares, a decrease of 31.1% from the December 31st total of 1,450,000 shares. Approximately 2.5% of the company's stock are short sold. Based on an average daily trading volume, of 1,580,000 shares, the short-interest ratio is presently 0.6 days.January 24, 2024 | msn.comShattuck Labs files to sell 3.1M shares for its holders Get Shattuck Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Everybody laughed when he recommended Netflix (Ad)"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. STTK Media Mentions By Week STTK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STTK News Sentiment▼0.360.42▲Average Medical News Sentiment STTK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STTK Articles This Week▼111▲STTK Articles Average Week Get Shattuck Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Verrica Pharmaceuticals News Today Korro Bio News Today Neurogene News Today Esperion Therapeutics News Today Mereo BioPharma Group News Today Terns Pharmaceuticals News Today Heron Therapeutics News Today Alto Neuroscience News Today Organogenesis News Today Amarin News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STTK) was last updated on 5/20/2024 by MarketBeat.com Staff From Our Partners"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shattuck Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
